Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer
Authors:
Open Access
- 22 September 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (9) , e2232787
Abstract
Importance: National Comprehensive Cancer Network guidelines currently recommend germline testing for high-risk genes in selected patients with breast cancer. The clinical utility of recommending testing all patients with breast cancer with multigene panels is currently under consideration.Objective: To examine the implications of universal testing of patients with breast cancer with respect to clinical decision-making.Design, Setting, and Participants: Patients from a previously reported cohort were assessed as in-criteria or out-of-criteria according to the 2017 guidelines and underwent testing with a multigene germline panel between 2017 to 2018. Patients were women and men aged 18 to 90 years, with a new and/or previous diagnosis of breast cancer who had not undergone either single or multigene testing. Clinicians from 20 community and academic sites documented patient clinical information and changes to clinical recommendations made according to test findings. Association between prevalence of pathogenic or likely pathogenic germline variants and previously unreported clinical features, including scores generated by the BRCAPRO statistical model, was determined. Data were analyzed from April 2020 to May 2022.Exposure: New and/or previous diagnosis of breast cancer.Main Outcomes and Measures: Disease management recommendations that were changed as a result of genetic testing results are reported.Results: Clinicians were asked to assess changes to clinical management as a result of germline genetic testing for 952 patients. Informative clinician-reported recommendations were provided for 939 (467 in-criteria and 472 out-of-criteria) of the patients with breast cancer (936 [99.7%] female; 702 [74.8%] White; mean [SD] age at initial diagnosis, 57.6 [11.5] years). One or more changes were reported for 31 of 37 (83.8%) in-criteria patients and 23 of 34 (67.6%) out-of-criteria patients with a pathogenic or likely pathogenic variant. Recommendations were changed as a result of testing results for 14 of 22 (63.6%) out-of-criteria patients who had a variant in a breast cancer predisposition gene. Clinicians considered testing beneficial for two-thirds of patients with pathogenic or likely pathogenic variants and for one-third of patients with either negative results or variants of uncertain significance. There was no difference in variant rate between patients meeting the BRCAPRO threshold (≥10%) and those who did not (P = .86, Fisher exact test). No changes to clinical recommendations were made for most patients with negative results (345 of 349 patients [98.9%]) or variants of uncertain significance (492 of 509 patients [96.7%]).Conclusions and Relevance: In this cohort study, germline genetic testing was used by clinicians to direct treatment for most out-of-criteria patients with breast cancer with pathogenic or likely pathogenic germline variants, including those with moderate-risk variants. Universal germline testing informs clinical decision-making and provides access to targeted treatments and clinical trials for all patients with breast cancer.Keywords
This publication has 35 references indexed in Scilit:
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationNew England Journal of Medicine, 2018
- Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast CancerJAMA Oncology, 2018
- Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population WomenJNCI: Journal of the National Cancer Institute, 2018
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationNew England Journal of Medicine, 2017
- Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer RiskAnnals of Surgical Oncology, 2017
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer SusceptibilityJournal of Clinical Oncology, 2015
- Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?Journal of Clinical Oncology, 2013
- Disparate Inclusion of Older Adults in Clinical Trials: Priorities and Opportunities for Policy and Practice ChangeAmerican Journal of Public Health, 2010
- BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility GenesJournal of Clinical Oncology, 2002
- Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.Journal of Clinical Oncology, 1996